|
業務類別
|
Biotechnology |
|
業務概覽
|
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform. |
| 公司地址
| 1091 Industrial Road, Suite 310, San Carlos, CA, USA, 94070 |
| 電話號碼
| +1 510 399-5001 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.attovia.com |
| 員工數量
| 44 |
| Mr. Tao Fu |
Director, Chief Executive Officer and President |
-- |
14/07/2026 |
| Mr. Steven Chan |
Chief Financial Officer and Principal Accounting Officer |
-- |
14/07/2026 |
| Dr. Zaneta Odrowaz |
Chief Business Officer, Treasurer and Secretary |
-- |
14/07/2026 |
| Mr. Petter Veiby |
Chief Scientific Officer |
-- |
14/07/2026 |
| Dr. Hubert Chen, M.D. |
Chief Medical Officer |
-- |
14/07/2026 |
|
|
| Dr. James N. Topper, M.D.,PhD |
Chairman of the Board |
14/07/2026 |
| Dr. Mitchell H. Gold,M.D. |
Independent Director |
14/07/2026 |
| Mr. John W. Smither |
Independent Director |
14/07/2026 |
| Mr. Tao Fu |
Director, Chief Executive Officer and President |
14/07/2026 |
| Dr. Angie You, PhD |
Independent Director |
14/07/2026 |
| Dr. Aaron Royston, M.D. |
Independent Director |
14/07/2026 |
| Dr. Colin Walsh, PhD |
Independent Director |
14/07/2026 |
| Dr. Rebecca Luse, M.D. |
Independent Director |
14/07/2026 |
|
|
|
|